Finding a sweet spot for leptin

Rebecca J Brown; Marc L Reitman

doi:10.1016/j.medj.2021.06.008

Finding a sweet spot for leptin

Med. 2021 Jul 9;2(7):794-796. doi: 10.1016/j.medj.2021.06.008.

Authors

Rebecca J Brown¹, Marc L Reitman²

Affiliations

¹ National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: brownrebecca@mail.nih.gov.
² National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

PMID: 35590217
DOI: 10.1016/j.medj.2021.06.008

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem that progresses to serious liver disease in some patients and for which there are no FDA-approved therapies. In this issue of Med, Akinci et al.¹ present encouraging preliminary data showing that treatment with recombinant leptin has beneficial effects on NAFLD.

Publication types

Research Support, N.I.H., Intramural
Comment

MeSH terms

Humans
Leptin* / therapeutic use
Non-alcoholic Fatty Liver Disease* / drug therapy

Substances

Leptin